MSF Access Campaign Calls On Mylan To Lower Price Of New TB Drug Delamanid In South Africa, Other Countries
Médecins Sans Frontières Access Campaign: MSF calls for new price of anti TB drug delamanid to be lowered and offered outside of South Africa
“Médecins Sans Frontières (MSF) acknowledges the lower price offered to the government of South Africa for newer anti tuberculosis (TB) drug, delamanid, but calls for it to be significantly lower and expanded to all countries in need. Mylan, which licenses the drug from the patent-holder Otsuka, will charge US$940 for a six-month treatment course ($157 per month) as of 1 June 2020 in South Africa. Delamanid is used in combination with other drugs to treat people with drug-resistant TB (DR-TB), including the hard to treat extensively drug-resistant TB (XDR-TB)…” (10/9).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.